JP2023523165A5 - - Google Patents

Info

Publication number
JP2023523165A5
JP2023523165A5 JP2022561181A JP2022561181A JP2023523165A5 JP 2023523165 A5 JP2023523165 A5 JP 2023523165A5 JP 2022561181 A JP2022561181 A JP 2022561181A JP 2022561181 A JP2022561181 A JP 2022561181A JP 2023523165 A5 JP2023523165 A5 JP 2023523165A5
Authority
JP
Japan
Prior art keywords
approximately
solid form
crystalline solid
mixture
xrpd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022561181A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023523165A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/025977 external-priority patent/WO2021207210A1/en
Publication of JP2023523165A publication Critical patent/JP2023523165A/ja
Publication of JP2023523165A5 publication Critical patent/JP2023523165A5/ja
Priority to JP2026032793A priority Critical patent/JP2026097919A/ja
Pending legal-status Critical Current

Links

JP2022561181A 2020-04-07 2021-04-06 Chk1阻害剤の合成方法 Pending JP2023523165A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026032793A JP2026097919A (ja) 2020-04-07 2026-03-02 Chk1阻害剤の合成方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063006305P 2020-04-07 2020-04-07
US63/006,305 2020-04-07
PCT/US2021/025977 WO2021207210A1 (en) 2020-04-07 2021-04-06 Methods for synthesis of chk1 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026032793A Division JP2026097919A (ja) 2020-04-07 2026-03-02 Chk1阻害剤の合成方法

Publications (2)

Publication Number Publication Date
JP2023523165A JP2023523165A (ja) 2023-06-02
JP2023523165A5 true JP2023523165A5 (cg-RX-API-DMAC7.html) 2024-04-16

Family

ID=78024095

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022561181A Pending JP2023523165A (ja) 2020-04-07 2021-04-06 Chk1阻害剤の合成方法
JP2026032793A Pending JP2026097919A (ja) 2020-04-07 2026-03-02 Chk1阻害剤の合成方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026032793A Pending JP2026097919A (ja) 2020-04-07 2026-03-02 Chk1阻害剤の合成方法

Country Status (7)

Country Link
US (2) US12606550B2 (cg-RX-API-DMAC7.html)
EP (1) EP4132922A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023523165A (cg-RX-API-DMAC7.html)
CN (2) CN120441567A (cg-RX-API-DMAC7.html)
BR (1) BR112022020278A2 (cg-RX-API-DMAC7.html)
CA (1) CA3174222A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021207210A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120441567A (zh) 2020-04-07 2025-08-08 Crt先锋基金有限公司 Chk1抑制剂的合成方法
WO2026108769A1 (en) * 2024-11-19 2026-05-28 Groovy Medicine (Hangzhou) Ltd. Substituted 2- [ (5-cyanopyrazin-2-yl) amino] pyridines, their prodrugs and uses thereof

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773778A (en) 1972-01-24 1973-11-20 Squibb & Sons Inc Sulfur derivatives of pyrazolo (3,4-b)pyridines
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
PL188959B1 (pl) 1995-07-06 2005-05-31 Novartis Ag Pirolopirymidyny i sposoby ich wytwarzania
IL150524A0 (en) 2000-01-07 2003-02-12 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
JP4637481B2 (ja) 2001-10-19 2011-02-23 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド Cds1/chk2阻害剤および癌治療における化学療法または放射線療法の補助剤としての2−フェニルベンズイミダゾールおよびイミダゾ−[4,5]−ピリジン
IL161576A0 (en) 2001-10-26 2004-09-27 Aventis Pharma Inc Benzimidazoles and analogues and their use as protein kinases inhibitors
CA2464934A1 (en) 2001-10-31 2003-05-08 Bayer Healthcare Ag Pyrimido [4,5-b] indole derivatives
AU2003234464B2 (en) 2002-05-03 2009-06-04 Exelixis, Inc. Protein kinase modulators and methods of use
AU2003243318A1 (en) 2002-05-29 2003-12-19 Millennium Pharmaceuticals, Inc. Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer
AU2004260689B8 (en) 2003-07-29 2008-05-15 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2005034869A2 (en) 2003-10-08 2005-04-21 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2005037825A2 (en) 2003-10-14 2005-04-28 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein kinase inhibitors
WO2005037285A1 (en) 2003-10-16 2005-04-28 Chiron Corporation 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of raf kinase for treatment of cancer
US20050096324A1 (en) 2003-11-05 2005-05-05 Zhi-Fu Tao Macrocyclic kinase inhibitors
US7163939B2 (en) 2003-11-05 2007-01-16 Abbott Laboratories Macrocyclic kinase inhibitors
US7642354B2 (en) 2004-04-13 2010-01-05 Icagen, Inc. Polycyclic pyrazines as potassium ion channel modulators
CN1243033C (zh) 2004-07-15 2006-02-22 合肥工业大学 一种通过内增韧制备薄膜级聚l-乳酸共聚物的方法
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
CN101189239A (zh) 2005-04-28 2008-05-28 休普基因公司 蛋白激酶抑制剂
EP1899322B1 (en) 2005-06-28 2009-09-02 Sanofi-Aventis Isoquinoline derivatives as inhibitors of rho-kinase
PE20070335A1 (es) 2005-08-30 2007-04-21 Novartis Ag Benzimidazoles sustituidos y metodos para su preparacion
PE20070543A1 (es) 2005-10-06 2007-06-14 Schering Corp Pirazolopirimidinas como inhibidores de protein quinasas
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
GB0616747D0 (en) 2006-08-24 2006-10-04 Astrazeneca Ab Novel compounds
SA07280004B1 (ar) * 2006-02-02 2011-10-29 استرازينيكا ايه بي ملح سترات من مركب 2- هيدروكسي –3- [5- (مورفولين –4- يل ميثيل) بيريدين –2- يل] 1h- إندول –5- كربونيتريل سترات
AU2007338410B2 (en) 2006-12-27 2012-08-16 Sanofi-Aventis Cycloalkylamine substituted isoquinoline derivatives
EP2134689B1 (en) 2007-03-16 2014-04-23 The Scripps Research Institute Inhibitors of focal adhesion kinase
WO2008117050A1 (en) 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
RU2009147819A (ru) 2007-05-25 2011-06-27 Астразенека Аб (Se) Комбинация ингибиторов снк и parp для лечения злокачественных новообразований
US8618121B2 (en) 2007-07-02 2013-12-31 Cancer Research Technology Limited 9H-pyrimido[4,5-B]indoles, 9H-pyrido[4',3':4,5]pyrrolo[2,3-D]pyridines, and 9H 1,3,6,9 tetraaza-fluorenes as CHK1 kinase function inhibitors
GB0719644D0 (en) 2007-10-05 2007-11-14 Cancer Rec Tech Ltd Therapeutic compounds and their use
WO2009099601A2 (en) 2008-02-04 2009-08-13 Dana-Farber Cancer Institute, Inc. Chk1 suppresses a caspase-2 apoptotic response to dna damage that bypasses p53, bcl-2 and caspase-3
GB0803018D0 (en) 2008-02-19 2008-03-26 Cancer Rec Tech Ltd Therapeutic compounds and their use
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
US8481557B2 (en) 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
US8865726B2 (en) * 2009-09-03 2014-10-21 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors
JP5808818B2 (ja) 2010-11-25 2015-11-10 ラツィオファーム・ゲーエムベーハー アファチニブの新規塩及び多形形態
US9345705B2 (en) 2011-09-15 2016-05-24 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
WO2013068755A1 (en) 2011-11-09 2013-05-16 Cancer Research Technology Limited 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use
EP2793882A4 (en) 2011-12-22 2015-04-29 Threshold Pharmaceuticals Inc ADMINISTRATION OF HYPOXIA-ACTIVATED PRODRUGS IN COMBINATION WITH CHK1 INHIBITORS FOR THE TREATMENT OF CANCER
CA2860665A1 (en) 2012-01-05 2013-07-11 Dana-Farber Cancer Institute, Inc. Methods of treating cancer
JP6027230B2 (ja) * 2012-05-15 2016-11-16 キャンサー・リサーチ・テクノロジー・リミテッド 5−[[4−[[モルホリン−2−イル]メチルアミノ]−5−(トリフルオロメチル)−2−ピリジル]アミノ]ピラジン−2−カルボニトリルおよびその治療上の使用
CN102675858A (zh) 2012-05-22 2012-09-19 同济大学 一种具有形状记忆功能可降解泪管栓塞的制备方法
GB201316526D0 (en) 2013-09-17 2013-10-30 King S College London Biomarkers
WO2015077602A1 (en) 2013-11-22 2015-05-28 Fred Hutchinson Cancer Research Center Methods for identifying therapeutic targets and treating and monitoring cancers
JP2017515859A (ja) 2014-05-15 2017-06-15 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 抗pd−1抗体と他の抗癌剤の組み合わせを使用する肺癌の処置
SG10201913151TA (en) 2015-09-09 2020-03-30 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Genetic engineering of macrophages for immunotherapy
US11725247B2 (en) 2016-02-29 2023-08-15 Foundation Medicine, Inc. Methods of treating cancer
WO2018102613A2 (en) 2016-12-01 2018-06-07 Nantomics, Llc Tumor antigenicity processing and presentation
WO2018191299A1 (en) 2017-04-10 2018-10-18 Sierra Oncology, Inc. Chk1(sra737)wee1 inhibitor combination methods of inhibiting tumor growth
MX2019012176A (es) 2017-04-10 2020-02-19 Sierra Oncology Inc Metodos de combinacion de chk1(sra737)/parpi para inhibir el crecimiento tumoral.
AU2018278336A1 (en) 2017-06-01 2020-01-16 Crt Pioneer Fund Lp Biomarkers and patient selection strategies
WO2019012030A1 (en) 2017-07-13 2019-01-17 INSERM (Institut National de la Santé et de la Recherche Médicale) DHODH INHIBITOR AND CHK1 INHIBITOR FOR THE TREATMENT OF CANCER
JP2021514979A (ja) 2018-02-26 2021-06-17 シエラ オンコロジー, インコーポレイテッド Chk1阻害剤を含む癌の治療方法
CA3135165A1 (en) 2019-03-28 2020-10-01 Sierra Oncology, Inc. Methods of treating cancer with chk1 inhibitors
AU2020274164A1 (en) 2019-05-14 2021-11-25 Sierra Oncology, Inc. Methods of treating cancer using Chk1 inhibitors
CN120441567A (zh) 2020-04-07 2025-08-08 Crt先锋基金有限公司 Chk1抑制剂的合成方法

Similar Documents

Publication Publication Date Title
JP5535082B2 (ja) ボセンタン、その多形形態及びその塩の合成方法
CN101573368B (zh) 结晶型1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯半水合物
JP2025176008A5 (cg-RX-API-DMAC7.html)
CN102448963B (zh) 7-[(3R,4R)-3-羟基-4-羟基甲基-吡咯烷-1-基甲基]-3,5-二氢-吡咯并[3,2-d]嘧啶-4-酮的有用药学上的盐
JP2013538849A5 (cg-RX-API-DMAC7.html)
TWI572594B (zh) 卡巴利他索(cabazitaxel)之結晶型及其製備方法
US8158607B2 (en) Crystalline form of lamivudine
CN103842359A (zh) N-[5-(氨基磺酰基)-4-甲基-1,3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)苯基]乙酰胺甲磺酸盐一水合物
EP0579681B1 (en) Crystalline tiagabine hydrochloride monohydrate, its preparation and use
WO2018007927A1 (en) Process for preparation of palbociclib
CN102060753B (zh) 一种4-苯胺基哌啶类镇痛药的精制方法
JP2023122634A (ja) トリエチレンテトラミン四塩酸塩、その製造方法及び組成物
US10870654B2 (en) Pharmaceutically acceptable salts and polymorphic forms of hydrocodone benzoic acid enol ester and processes for making same
JP2022060192A5 (cg-RX-API-DMAC7.html)
TW202233205A (zh) 莫奈皮拉韋之醫藥同質異晶物
WO2007013086A1 (en) Novel polymorphs of tenofovir disoproxil fumarate
JP2023517729A5 (cg-RX-API-DMAC7.html)
JP2022540678A5 (cg-RX-API-DMAC7.html)
CA2794389A1 (en) Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers
KR100830002B1 (ko) 시부트라민의 무기산염
JP5257353B2 (ja) 置換ヒドロキシメチルフェノールの新規な合成
WO2019037591A1 (zh) 盐酸美法仑晶型及其制备方法与应用
JP2025531538A (ja) イナボグリフロジンの新規な共結晶
WO2005023769A1 (en) Process for the preparation of amlodipine salts
US11111208B2 (en) Process for the preparation of safinamide mesylate intermediate